NCT00238654

Brief Summary

This study has patients responding to two sets of surveys that will tell their doctor or nurse about their readiness to begin self-injection. In addition, patients will have their self-injection observed and evaluated on up to three visits

Trial Health

100
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
257

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started May 2003

Longer than P75 for all trials

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

May 1, 2003

Completed
2.5 years until next milestone

First Submitted

Initial submission to the registry

October 12, 2005

Completed
1 day until next milestone

First Posted

Study publicly available on registry

October 13, 2005

Completed
2.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 1, 2008

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

July 1, 2008

Completed
Last Updated

April 12, 2011

Status Verified

April 1, 2011

Enrollment Period

5.2 years

First QC Date

October 12, 2005

Last Update Submit

April 8, 2011

Conditions

Outcome Measures

Primary Outcomes (1)

  • Adherence of self-injection assessed by self-report at each follow-up visit

    12 months

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

RRMS patient with treatment-naïve or treatment-experienced

You may qualify if:

  • Male or Female, 18 years of age or older, with diagnosis of RRMS
  • Naive to treatment or previously treated with an IFN.

You may not qualify if:

  • Not eligible for treatment based on clinical criteria and current indication.
  • Unable to respond to surveys or provide informed consent.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Multiple Sclerosis

Condition Hierarchy (Ancestors)

Demyelinating Autoimmune Diseases, CNSAutoimmune Diseases of the Nervous SystemNervous System DiseasesDemyelinating DiseasesAutoimmune DiseasesImmune System Diseases

Study Officials

  • MerriKay Oleen-Burkey, Ph.D.

    Teva Neuroscience, Inc.

    STUDY DIRECTOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
INDUSTRY

Study Record Dates

First Submitted

October 12, 2005

First Posted

October 13, 2005

Study Start

May 1, 2003

Primary Completion

July 1, 2008

Study Completion

July 1, 2008

Last Updated

April 12, 2011

Record last verified: 2011-04